Back to Journals » OncoTargets and Therapy » Volume 11

Stereotactic body radiotherapy using the CyberKnife® system in the treatment of patients with liver metastases: state of the art

Authors Ihnát P, Skácelíková E, Tesař M, Penka I

Received 19 February 2018

Accepted for publication 4 June 2018

Published 10 August 2018 Volume 2018:11 Pages 4685—4691

DOI https://doi.org/10.2147/OTT.S165878

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 2

Editor who approved publication: Dr Jianmin Xu


Peter Ihnát,1,2 Eva Skácelíková,3 Milan Tesař,1,2 Igor Penka1,2

1Department of Surgery, University Hospital Ostrava, Ostrava, Czech Republic; 2Department of Surgical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; 3Department of Oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

Background: The management of patients with liver metastases presents a challenging problem in clinical oncology. Patients with limited involvement of the liver may be suitable for surgical resection or local ablative techniques. Stereotactic body radiotherapy (SBRT) presents an emerging new technology that has shown high efficacy in ablating tumors at various disease sites.
Methods: A comprehensive literature search was performed to identify articles in regard to the SBRT in the treatment of patients with liver metastases.
Results: SBRT allows for the delivery of high-dose radiation in few fractions to the tumor with extreme accuracy, while minimizing the damage to normal surrounding tissue. The CyberKnife® system is an image-guided robotic system that delivers SBRT, tracks tumors during respiration, and automatically adjusts treatment for any patient movement. The most frequently used indications for CyberKnife® therapy are ≤5 liver metastases with maximum tumor sizes of 6 cm, no extrahepatic disease, good performance status, and adequate hepatic functions. Local control rates range from 70%–100% at 1 year and from 60%–90% at 2 years. Severe toxicity related to SBRT is uncommon – grade three side effects occur in less than 5% of cases. Despite excellent local control rates, out-of-field metastatic progression (out-of-field hepatic metastases and extrahepatic metastases) develops in a substantial proportion of patients after SBRT. Therefore, it seems essential to improve the selection of patients with liver metastases for SBRT.
Conclusion: The CyberKnife® system presents an effective minimally invasive treatment modality for patients with hepatic oligometastases who are not suitable candidates for radical liver resection. The available data suggest that liver metastases can be treated by CyberKnife therapy with very low toxicity and excellent local control rates.

Keywords: CyberKnife, liver metastases, stereotactic body radiotherapy, indications, clinical outcomes, toxicity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]